Maria Jesús Vidal
Grupo de investigación
- Genómica traslacional y terapias dirigidas en tumores sólidos Accredited researcher (R3A)
Publicaciones destacadas
-
Sentinel node after NeoAdjuvancy in node-positive breast cancer. SANA multicentric study
Autores:Referencia: European Journal Of Cancer 2020. -
Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Phase 1 and Randomized Phase 2 Trial
Autores:Referencia: Jama Oncology 2020. -
Frequency and spectrum of PIK3CA somatic mutations in breast cancer
Autores:Referencia: Breast Cancer Research 2020. -
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis
Autores:Referencia: Cancer Treatment Reviews 2020. -
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
Autores:Referencia: Nature Communications 2020. -
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade
Autores:Referencia: Journal Of The National Cancer Institute 2020. -
PAM50MET: A prognostic model based on PAM50 and clinical variables in metastatic hormone receptor (HR)-positive/HER2 negative breast cancer
Autores:Referencia: Annals Of Oncology 2019.
Proyectos destacados
-
HER2-enriched molecular subtype as a predictor of response to dual HER2 blockade.
Investigador/a principal: Aleix PratFinanciador: Beca Susan Komen (Sede o evento)Duración: 01/01/2014 - 01/01/2016 -
Predictores de Respuesta a la Quimioterapia en Cáncer de Mama Triple-Negativo con un Perfil Molecular Basal-like.
Investigador/a principal: Aleix PratFinanciador: Beca Sandra Ibarra (Sede o evento)Duración: 01/01/2013 - 01/01/2013 -
Molecular Quantification of Estrogen Receptor Partners for Endocrine Response Prediction.
Financiador: Universidad de Oslo (Sede o evento)Duración: 01/01/2012 - 01/01/2016